Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy

Phase 2

Recruiting

• Conditions: Drug Resistant Epilepsy
• Interventions: Drug: Lactobacillus-Based Capsule

• Registration Number: NCT05539287
• Lead Sponsor: Tanta University

Brief Summary

Animal and human studies have brought up evidence supporting Gut microbial disbalance, namely dysbiosis, as a causative factor of epilepsy, especially the refractory form. thus, probiotics might constitute a safe, low-cost, and effective supplementary therapy in patients with DRE.

The Lactobacillus population is probiotic bacteria that have a beneficial role in epilepsy. Lactobacillus can influence brain function through the modulation of GABA, as shown in rodent models. Moreover, it has been demonstrated in animal models of epilepsy and in human epileptic patients that probiotic treatment aimed at restoring gut microbiota equilibrium has beneficial effects on epileptic symptoms by increasing GABA in animals and the levels of Bifidobacteria and Lactobacillus in humans.

Detailed Description

This study will be a placebo-controlled, double-blind, and parallel 6-month duration study

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2022-09-10
• Study First Submitted QC: 2022-09-10
• Study First Posted: 2022-09-14
• Study Start: 2022-09-25
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-06
• Last Update Posted: 2022-10-10
• Primary Completion: 2024-08
• Study Completion: 2025-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients aged 3-18 years with intractable childhood-onset epilepsy.

  • All patients are diagnosed to have drug-resistant epilepsy (refractory epilepsy) according to the ILAE definition.
  • The subject is willing and able to comply with the study requirements

Read More

Exclusion Criteria

• Any metabolic conditions that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR < 60 mL/min/1.73 m2 or electrolyte imbalance.

  • Patients who are currently using or used antibiotics therapy in the preceding month
  • Patients who are currently using or used other probiotic products in the preceding two weeks
  • Patients scheduled to undergo GIT surgery or those who underwent GIT surgery
  • Patients with a Known allergy to probiotics.
  • Patients receiving artificial enteral or intravenous nutrition

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Lactobacillus-Based Capsule	25 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
Probiotic Group	Lactobacillus-Based Capsule	25 patients will receive Lactobacillus species 5 billion colony forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.

Primary Outcome Measures

Name	Time	Method
effectivness of Lactobacillus probiotics for controlling epileptic seizures in children with drug resistant epilepsy	6 months	effectivness can be defined as more than 50% reduction in number of seizures.

Secondary Outcome Measures

Name	Time	Method
1. the change in the concentration of measured biological parameters (NLRP3, and GAD-Ab)	6 months	Before and 6 months after intervention, 5 ml of venous blood will be withdrawn from each participant by antecubital venipuncture between 8 am and 11 am. Blood samples will be centrifuged at 3000 rpm for 15 min to separate sera. Sera will be kept at deep freeze (-80°C) until analysis of serum concentrations of : * Serum NLRP3 inflammasome level.; * Serum glutamic acid decarboxylase antibody (GAD-Ab).

Trial Locations

Locations (1)

Amira; 🇪🇬 Tanta, Egypt